88.14
0.34 (0.39%)
| Previous Close | 87.80 |
| Open | 86.53 |
| Volume | 1,348,420 |
| Avg. Volume (3M) | 1,034,282 |
| Market Cap | 5,058,001,920 |
| Price / Earnings (Forward) | 1.67 |
| Price / Sales | 10.95 |
| Price / Book | 6.33 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Glaukos Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 122.00 (Wells Fargo, 38.42%) | Buy |
| Median | 117.00 (32.74%) | |
| Low | 103.00 (Goldman Sachs, 16.86%) | Buy |
| Average | 115.86 (31.45%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 86.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 30 Oct 2025 | 116.00 (31.61%) | Buy | 87.80 |
| 20 Oct 2025 | 104.00 (17.99%) | Buy | 79.47 | |
| Citigroup | 30 Oct 2025 | 113.00 (28.21%) | Buy | 87.80 |
| 07 Oct 2025 | 110.00 (24.80%) | Buy | 84.09 | |
| JP Morgan | 30 Oct 2025 | 120.00 (36.15%) | Buy | 87.80 |
| Needham | 30 Oct 2025 | 117.00 (32.74%) | Buy | 87.80 |
| Wells Fargo | 30 Oct 2025 | 122.00 (38.42%) | Buy | 87.80 |
| 27 Oct 2025 | 120.00 (36.15%) | Buy | 75.68 | |
| Goldman Sachs | 01 Oct 2025 | 103.00 (16.86%) | Buy | 83.19 |
| Truist Securities | 22 Sep 2025 | 120.00 (36.15%) | Buy | 84.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Nov 2025 | Announcement | Glaukos Announces Participation in Upcoming Investor Conferences |
| 29 Oct 2025 | Announcement | Glaukos Announces Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Announcement | Glaukos Announces FDA Approval of Epioxa™ |
| 14 Oct 2025 | Announcement | Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting |
| 08 Oct 2025 | Announcement | Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 |
| 25 Sep 2025 | Announcement | Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama |
| 13 Aug 2025 | Announcement | Glaukos Announces Participation in Wells Fargo Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |